REGULATORY

Komeito Petitions Govt for Market Incentives for Meiji’s Novel Antibacterial

March 2, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Komeito submitted a petition to the Japanese government on February 28 asking them to introduce market incentives for and support the domestic production of nacubactam, an antibacterial for antimicrobial-resistant bacteria being developed by Meiji Seika Pharma. The petition was submitted…

To read the full story

Global PIII Launched for Novel β-Lactamase Inhibitor Nacubactam: Meiji
April 27, 2023
Japan to Lead Discussions on AMR Measures at G7 Summit: PM
March 7, 2023
Komeito Poised to Call for Govt Support on Meiji Pharma’s Nacubactam
February 27, 2023

REGULATORY

Chuikyo OKs Listing of J&J’s Rybrofaz, Peak Sales Seen at 43.8 Billion Yen
March 12, 2026
Truqap Price Cut Set at 10.7% from June under CEA Scheme
March 12, 2026
Council Floats 9.6% Growth Target for Japan’s On-Patent Drug Market
March 11, 2026
MHLW Approves Towa Generics for Revolade, Vimpat
March 11, 2026
Panel Clears Zolgensma Intrathecal Form to Expand Use in Older SMA Patients
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…